COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.489
-0.079 (-2.21%)
Jun 18, 2025, 4:00 PM - Market closed
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $1.50M in the quarter ending March 31, 2025, a decrease of -27.08%. This brings the company's revenue in the last twelve months to $9.03M, up 36.51% year-over-year. In the year 2024, COSCIENS Biopharma had annual revenue of $9.59M with 34.22% growth.
Revenue (ttm)
$9.03M
Revenue Growth
+36.51%
P/S Ratio
1.23
Revenue / Employee
$225,750
Employees
40
Market Cap
11.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.59M | 2.44M | 34.22% |
| Dec 31, 2023 | 7.14M | -7.43M | -50.98% |
| Dec 31, 2022 | 14.57M | 9.31M | 177.03% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CSCI News
- 24 days ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 5 weeks ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 3 months ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewsWire
- 7 months ago - COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs - GlobeNewsWire